Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 May 10;16(10):1825. doi: 10.3390/cancers16101825

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Results from a Cox proportional hazards model for overall survival with terms for TMB (numerical), PDL1 (binary, high vs. low\medium), the treatment (ipilimumab-nivolumab vs. pembrolizumab), and the two covariate-by-treatment interactions. *** High PDL1 was associated with reduced hazard compared to low-medium PDL1 (HR = 0.5, 95% CI [0.3, 0.84], p = 0.01). ** Ipilimumab-nivolumab treatment was associated with reduced hazard compared to pembrolizumab treatment (HR = 0.65, 95% CI [0.43, 0.99], p = 0.05). * The terms for TMB and for the treatment-by-covariate interactions were not statistically significant.